Argon Laser Study Ongoing For Age Related Macular Degeneration Treatment
This article was originally published in The Gray Sheet
Executive SummaryPatient enrollment for a five-year, National Eye Institute-sponsored trial to evaluate argon laser coagulation of the retina for prevention of age-related macular degeneration (AMD) will be complete by November 2000, staffers at the University of Pennsylvania's Scheie Center for Preventive Ophthalmology report.
You may also be interested in...
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.
Momenta Pharmaceuticals has agreed to pay $35.0m to settle claims that it manipulated generic approval processes in the US to shut competitor Amphastar out of the US enoxaparin market.